|
| Status |
Public on Mar 01, 2021 |
| Title |
KIR Polymorphism is Associated with Primary Resistance to PD-1 Blockade in Lung Cancer |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Adaptive immune escape of tumor cells by upregulation of ligands for programmed death 1 (PD-1) has been identified as an important and targetable pathway in many cancer types. Many clinical trials have demonstrated that targeting PD-1 or its ligand PD-L1 with immune checkpoint inhibitors (ICI) can restore anti-tumor immunity and induce durable remission. In patients with non-small cell lung cancer (NSCLC), several trials have demonstrated a survival benefit with ICI in patients with metastatic and locally advanced NSCLC.Yet, most patients have primary resistance to PD-1 or PD-L1 blockade during treatment: approximately 20% of unselected patients with NSCLC achieve a partial response while 40-50% have progressive disease as best response. Understanding mechanisms of primary resistance to PD-(L)1 blockade is important in the search for potentially targetable pathways and may ultimately allow discrimination between patients that benefit from PD-(L)1 blockade and those requiring combination or other approaches. We collected PBMCs and serum samples from 35 patients with NSCLC before and during PD-1 blockade treatment with nivolumab. We analyzed differentially expressed genes in CD8+ T cells from the peripheral blood of 5 patients with partial response and 5 patients with primary progressive disease to identify mechanisms of resistance to PD-1 therapy. Cells were collected from samples taken before and after 4 weeks of treatment.
|
| |
|
| Overall design |
Peripheral blood mononuclear cells (PBMCs) were prospectively collected from metastatic NSCLC patients (discovery cohort) just before the first administration (N1) and during treatment (at 4 weeks, N2) with PD-1 blockade. Patiens were classified to either "responder"(partial response PR) or "nonresponder" (progressive disease PD) based on objective radiological response by RECIST by a thoraic radiologist. From 5 responder and 5 nonresponder patients peripheral CD8+ T cells were sorted by fluorescence activated cell sorting using a BD FACS AriaIII and RNA isolated from these cells. We investigated changes in RNA expression upon treatment wit PD-1 blockade associated with clinical response.
|
| |
|
| Contributor(s) |
Läubli H, Trefny MP, Uhlenbrock F, Herzig P, Thommen DS, Savic S, Schaub S, Stenner F, Rothschild S, Zippelius A |
| Citation(s) |
30765392 |
| Submission date |
Mar 05, 2018 |
| Last update date |
Apr 27, 2021 |
| Contact name |
Heinz Läubli |
| E-mail(s) |
heinz.laeubli@unibas.ch
|
| Phone |
+41 61 556 5212
|
| Organization name |
University of Basel
|
| Department |
Department of Biomedicine
|
| Lab |
Medical Oncology and Cancer Immunology
|
| Street address |
Hebelstrasse 20
|
| City |
Basel |
| ZIP/Postal code |
4031 |
| Country |
Switzerland |
| |
|
| Platforms (1) |
| GPL21290 |
Illumina HiSeq 3000 (Homo sapiens) |
|
| Samples (20)
|
|
| Relations |
| BioProject |
PRJNA436957 |
| SRA |
SRP133939 |
Less...
More...